Form 4: Recursion Pharmaceuticals Director Terry-Ann Burrell Reports Stock and Option Awards

Director Terry-Ann Burrell reports acquisition of restricted stock units and stock options in Recursion Pharmaceuticals.

Summary

• On June 3, 2024, Terry-Ann Burrell, a director of Recursion Pharmaceuticals, reported the acquisition of 13,097 shares of Class A Common Stock and stock options for 26,193 shares.
• The shares were granted as restricted stock units and the options were granted pursuant to the Issuer's Outside Director Compensation Policy.
• The restricted stock units will vest on the earlier of June 3, 2025, or the day prior to the Issuer's 2025 annual meeting of stockholders, subject to continued service.
• The stock options will vest and become exercisable on the earlier of June 3, 2025, or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to continued service.
• Following the transaction, Burrell directly owns 69,411 shares of Class A Common Stock and options for 26,193 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices for directors, aligning their interests with shareholders.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedules tied to continued service incentivize the director to remain with the company.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of stock and option awards to a company director, which is a common practice in publicly traded companies to incentivize and retain key personnel.

Stakeholder Impact

• The stock and option awards could have a slightly dilutive effect on existing shareholders.
• The awards incentivize the director to contribute to the long-term success of the company, benefiting all stakeholders.

Key Dates